Overview
Evolent Health, Inc., based in the United States, operates within the healthcare sector, primarily focused on providing an integrated, value-based care platform to payers and providers. The company aids its partners in driving high-quality, lower-cost care by delivering comprehensive clinical and administrative solutions. Evolent Health’s key projects typically involve assisting organizations in transitioning from fee-for-service to value-based care models. This includes offering software, analytics, and clinical technology services that help manage risk and improve patient outcomes. Their strategic approach not only supports the operational needs of healthcare entities but also aligns with evolving regulatory and reimbursement frameworks, thereby facilitating a more sustainable and efficient healthcare system.
AI+ Ask Fintel’s AI assistant about Evolent Health, Inc..
Thinking about good questions…
Basic Stats
The share price of Evolent Health, Inc. as of September 8, 2025 is $9.66 / share. This is an increase of 0.10% from the prior week. The market cap (or net worth) of Evolent Health, Inc. as of September 8, 2025 is $1,119.93 MM.
The Factor Analysis chart (below right) shows a view of Evolent Health, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 1,119.93 MM |
| EV | 2,190.43 MM |
| Shares Out. | 115.94 MM |
| Earnings Date | |
| EPS (TTM) | -1.13 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.39 |
| Short Shares Avail. | 0.70 MM |
| Short Interest | 20.29 MM |
| Short Float | 22.22 % |
| Days to Cover | 14.08 days |
| Risk Free Rate | 4.10 % |
| Price Change (1 yr) | -68.34 % |
| Volatility (1 yr) | 0.77 |
| Beta | 0.07 |
| Sharpe Ratio (1 yr) | -0.94 |
| Sortino Ratio (1 yr) | -1.22 |
| PE Ratio | -8.58 |
| Price/Book | 1.00 |
| Price/TBV | -1.25 |
| Book/Market | 1.00 |
| EBIT/EV | -0.06 |
| EBIT(3yr avg)/EV | -0.06 |
| ROA | -0.05 |
| ROE | -0.11 |
| ROIC | -0.06 |
| CROIC | 0.02 |
| OCROIC | -0.02 |
| Implied Volatility | 69.87 % |
| Put/Call OI Ratio | 0.47 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Evolent Health, Inc. is $15.98. The forecasts range from a low of $9.09 to a high of $21.00. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Evolent Health, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-11-18 | Cowen & Co. | Outperform | Maintains | |
| 2022-11-04 | Piper Sandler | Overweight | Maintains | |
| 2022-11-01 | Truist Securities | Hold | Initiate | |
| 2022-10-12 | Canaccord Genuity | Buy | Maintains | |
| 2022-10-12 | BTIG | Buy | Maintains | |
| 2022-08-19 | JP Morgan | Overweight | Maintains | |
| 2022-08-03 | RBC Capital | Outperform | Maintains | |
| 2022-08-03 | Piper Sandler | Overweight | Maintains | |
| 2022-08-03 | BTIG | Buy | Maintains | |
| 2022-07-29 | RBC Capital | Outperform | Initiate | |
| 2022-06-21 | Cowen & Co. | Outperform | Maintains | |
| 2022-05-09 | Canaccord Genuity | Buy | Maintains | |
| 2022-03-30 | Guggenheim | Buy | Initiate | |
| 2022-03-25 | BTIG | Buy | Maintains | |
| 2021-11-18 | JP Morgan | Neutral | Overweight | Upgrade |
| 2021-08-05 | Canaccord Genuity | Buy | Maintains | |
| 2021-03-01 | Canaccord Genuity | Buy | Maintains | |
| 2021-01-07 | BTIG | Buy | Initiate | |
| 2020-07-20 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-07-20 | Baird | Outperform | Maintains | |
| 2020-07-06 | KeyBanc | Overweight | Sector Weight | Downgrade |
| 2020-06-05 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2020-06-02 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2020-05-08 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-03-26 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-02-26 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2020-01-23 | Cantor Fitzgerald | Overweight | Maintains | |
| 2020-01-08 | Wells Fargo | Overweight | Maintains | |
| 2019-12-02 | KeyBanc | Overweight | Maintains | |
| 2019-11-27 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2019-11-06 | Piper Jaffray | Overweight | Maintains | |
| 2019-03-04 | KeyBanc | Overweight | Overweight | Maintains |
| 2019-02-27 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2018-10-04 | Citigroup | Buy | Buy | Maintains |
| 2018-09-13 | KeyBanc | Overweight | Overweight | Maintains |
| 2018-09-13 | Canaccord Genuity | Buy | Buy | Maintains |
| 2018-08-20 | KeyBanc | Overweight | Overweight | Maintains |
| 2018-06-07 | KeyBanc | Overweight | Overweight | Maintains |
| 2018-06-04 | PiperJaffray | Overweight | Initiate | |
| 2018-05-30 | KeyBanc | Overweight | Overweight | Maintains |
| 2018-02-28 | Wells Fargo | Outperform | Maintains | |
| 2018-02-28 | Canaccord Genuity | Buy | Buy | Maintains |
| 2017-09-28 | Baird | Outperform | Maintains | |
| 2017-09-20 | KeyBanc | Overweight | Initiate | |
| 2017-06-02 | Baird | Outperform | Initiate | |
| 2017-01-06 | Cantor Fitzgerald | Overweight | Initiate | |
| 2016-07-26 | Jefferies | Buy | Initiate | |
| 2016-03-29 | FBR Capital | Outperform | Initiate | |
| 2016-03-14 | JP Morgan | Overweight | Maintains | |
| 2016-01-20 | Cowen & Co. | Outperform | Initiate | |
| 2016-01-06 | Canaccord Genuity | Buy | Initiate | |
| 2015-08-07 | JP Morgan | Overweight | Maintains | |
| 2015-06-30 | William Blair | Outperform | Initiate | |
| 2015-06-30 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2015-06-30 | JP Morgan | Overweight | Initiate | |
| 2015-06-30 | Goldman Sachs | Buy | Initiate | |
| 2023-01-30 | Cowen & Co. | Outperform | Maintains | |
| 2023-02-23 | RBC Capital | Outperform | Reiterate | |
| 2023-05-04 | Stephens & Co. | Overweight | Reiterate | |
| 2023-04-12 | Stephens & Co. | Overweight | Initiate | |
| 2023-05-24 | RBC Capital | Outperform | Reiterate | |
| 2024-03-28 | Canaccord Genuity | Buy | Buy | Maintains |
| 2023-06-26 | Guggenheim | Buy | Buy | Maintains |
| 2023-10-16 | UBS | Buy | Initiate | |
| 2023-08-14 | Guggenheim | Buy | Buy | Reiterate |
| 2023-11-14 | Truist Securities | Hold | Hold | Maintains |
| 2023-12-06 | JMP Securities | Market Outperform | Initiate | |
| 2023-11-28 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-03-15 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-05-10 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-05-10 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-04-22 | Citigroup | Buy | Initiate | |
| 2024-03-01 | Oppenheimer | Outperform | Initiate | |
| 2024-02-23 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-02-23 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2025-01-23 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-08-09 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-08-09 | Truist Securities | Hold | Buy | Upgrade |
| 2024-11-08 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-11-08 | Stephens & Co. | Overweight | Equal-Weight | Downgrade |
| 2025-01-15 | Needham | Buy | Buy | Reiterate |
| 2025-01-14 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-11-12 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-01-28 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-07-30 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2024-08-26 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-10-11 | Keybanc | Overweight | Initiate | |
| 2024-08-27 | Truist Securities | Buy | Buy | Maintains |
| 2025-05-13 | Needham | Buy | Buy | Reiterate |
| 2025-02-12 | Needham | Buy | Buy | Reiterate |
| 2024-11-22 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-01-24 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-11-13 | Citigroup | Buy | Buy | Maintains |
| 2024-10-29 | Citigroup | Buy | Buy | Maintains |
| 2024-08-19 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-02-24 | Citizens Capital Markets | Market Outperform | Market Outperform | Maintains |
| 2025-01-10 | Needham | Buy | Initiate | |
| 2024-10-08 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-01-21 | Stephens & Co. | Equal-Weight | Equal-Weight | Maintains |
| 2025-01-10 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2025-01-10 | Citigroup | Buy | Buy | Maintains |
| 2025-02-21 | Needham | Buy | Buy | Reiterate |
| 2025-01-16 | UBS | Buy | Buy | Maintains |
| 2025-02-14 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-11-18 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-11-11 | Barclays | Overweight | Overweight | Maintains |
| 2025-02-21 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2025-08-28 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-01-22 | Truist Securities | Buy | Buy | Maintains |
| 2025-01-13 | Truist Securities | Buy | Buy | Maintains |
| 2025-05-09 | UBS | Buy | Buy | Maintains |
| 2025-03-10 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-04-10 | Truist Securities | Buy | Buy | Maintains |
| 2025-07-17 | Truist Securities | Buy | Buy | Maintains |
| 2025-06-20 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-04-28 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
